In Colorado, miRagen Therapeutics, a biopharmaceutical company which develops microRNA-targeting therapies for treating diseases and cancer, has acquired Signal Genetics. The acquisition was funded partly by a $40 million investment by Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures, JAFCO Co., Ltd., MP Healthcare Venture Management, MRL Ventures (Merck), Remeditex Ventures, and others. Signal Genetics, a publicly traded company based in California, has been working on genetic testing technology for multiple myeloma. Signal’s name and stock symbol will be changed to that of miRagen Therapeutics, as miRagen acquired 96% of Signal’s stock. Signal’s executives and directors will all resign as part of the acquisition.
Latest article
UK utility extracting glucose from used TP
In the United Kingdom, water treatment company United Utilities is trialing a process at its Blackburn sewage works to extract glucose from used toilet...
Stella McCartney takes flight with plant-based feathers
In New York, sustainability-focused designer Stella McCartney used faux feathers made from plant-based materials in fashions exhibited at the recent Paris Fashion Week.
Produced...
Artificial Nature hits milestone scaling PLH
In Germany, Artificial Nature S.L. has scaled up production of its biobased and biodegradable copolyester PLH to 300 metric tons per year. The milestone...